KBI Biopharma, a JSR Life Sciences company, wins global recognition for excellence in biologics manufacturing at the 2025 CDMO Leadership Awards.
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization challenges.